Prostate cancer trial tests whether adding hormone therapy to radiation boosts success

NCT ID NCT01492972

Recruiting now Disease control Sponsor: Proton Collaborative Group Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This phase 3 study is testing whether adding a short course of hormone therapy (androgen suppression) to image-guided radiation therapy helps men with intermediate-risk prostate cancer. About 192 men will receive either radiation alone or radiation plus hormone therapy. The goal is to see if the combination reduces the chance of cancer returning, while also tracking side effects and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Androgen suppression therapy (leuprolide, goserelin, buserelin, or triptorelin)
What this could lead to: If successful, this could show that adding short-term hormone therapy to radiation helps keep prostate cancer from coming back in men with intermediate-risk disease.
What could go wrong: This is an ongoing phase 3 trial, so results are not yet known. Hormone therapy can cause side effects like hot flashes, fatigue, and sexual problems, and it may not improve outcomes enough to justify those risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Hampton University Proton Therapy Institute
RECRUITING

Hampton, Virginia, 23666, United States
Mayo Clinic
RECRUITING

Scottsdale, Arizona, 85259-5499, United States
Northwestern Medicine Chicago Proton Center
RECRUITING

Warrenville, Illinois, 60555, United States
Oklahoma Proton Center
RECRUITING

Oklahoma City, Oklahoma, 73142, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.